Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLC

Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLC

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung CancerПодробнее

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung Cancer

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLCПодробнее

Suresh Ramalingam, MD, on how the FLAURA trial may impact care for EGFR-mutated NSCLC

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLCПодробнее

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Suresh Ramalingam, MD, FASCO, shares results from the FLAURA trial presented at ESMO 2019Подробнее

Suresh Ramalingam, MD, FASCO, shares results from the FLAURA trial presented at ESMO 2019

Dr. Hassan on FLAURA Trial Results in EGFR-Mutant NSCLCПодробнее

Dr. Hassan on FLAURA Trial Results in EGFR-Mutant NSCLC

Dr. Ramalingam on FLAURA Findings in EGFR-Mutant NSCLCПодробнее

Dr. Ramalingam on FLAURA Findings in EGFR-Mutant NSCLC

Dr. Ramalingam on the Significance of the FLAURA Trial in NSCLCПодробнее

Dr. Ramalingam on the Significance of the FLAURA Trial in NSCLC

The FLAURA Trial: Practice-Changing Results for EGFR Mutation-Positive NSCLC (BMIC-007)Подробнее

The FLAURA Trial: Practice-Changing Results for EGFR Mutation-Positive NSCLC (BMIC-007)

Dr. Ramalingam on the OS Results of the FLAURA Trial in EGFR-Mutant NSCLCПодробнее

Dr. Ramalingam on the OS Results of the FLAURA Trial in EGFR-Mutant NSCLC

FLAURA final analysis: osimertinib for first-line EGFRm NSCLCПодробнее

FLAURA final analysis: osimertinib for first-line EGFRm NSCLC